Helicobacter pylori에 대한 3차 제균 치료의 최신지견 = Recent Update on Third-line Helicobacter pylori Eradication

다국어 초록 (Multilingual Abstract)

The eradication rate of Helicobacter pylori has been decreasing progressively, primarily due to increased resistance to antibiotics. The widely used standard clarithromycin-based triple therapy regimen is no longer achieving eradication rate of 80% in intent-to-treat analysis in many countries. Due to the primary and secondary resistance to metronidazole, the key antibiotic for second line regimen, eradication rate of standard metronidazole based quadruple therapy is also decreasing. It is rational to check antibiotic resistance for selecting regimens in third-line rescue eradication therapy, but it requires time and resource. Limited studies regarding the efficacy of a dual regimen consisting of high dose proton pump inhibitor and amoxicillin showed controversial results. Efficacy of rescue regimens containing fluoroquinolones, such as levofloxacin and moxifloxacin, were reported to be insufficient due to increasing incidence of primary and secondary resistance. Eradication result of third-line rescue regimens with sitafloxacin, a novel quinolone of which the antibacterial activity towards H. pylori is more than 100-fold that of ciprofloxacin in vitro, is promising. Although prevalence of serious side effect such as myelotoxicity with rifabutin-based rescue regimen is reported to be lower than expected, wider use of rifabutin is still concerned regarding the emergence of resistant mycobacterial species. Rifaximin based rescue regimen is safer and cheaper than rifabuitin based regimen. However, further investigation for better eradication rates by enhancing higher drug concentration in the gastric mucus layer needs to be evaluated.

참고문헌 (Reference)

1 정명호, "헬리코박터 파일로리의 3차 구제요법에서 리파부틴과 레보플록사신의 비교" 대한소화기학회 59 (59): 401-406, 2012

2 이선영, "헬리코박터 치료의 새로운 가이드라인: 한국과 일본의 비교" 대한소화기학회 63 (63): 151-157, 2014

3 김재연, "한국인의 위·십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율" 대한소화기학회 58 (58): 74-81, 2011

4 김정목, "한국인 환자에서 분리한 Helicobacter pylori 균주의 항생제 내성률" 대한소화기학회 47 (47): 337-349, 2006

5 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013" 대한소화기학회 62 (62): 3-26, 2013

6 허준, "한국에서 헬리코박터 파일로리에 대한 삼제요법의 치료율 변화" 대한소화기학회 63 (63): 141-145, 2014

7 Yoon K, "Ultimate eradication rate of Helicobacter pylori after first, second, or third-line therapy in Korea" 30 : 490-495, 2015

8 Gisbert JP, "Thirdline rescue therapy with levofloxacin after two H. pylori treatment failures" 101 : 243-247, 2006

9 Gomollón F, "Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients" 14 : 1335-1338, 2000

10 Holton J, "The susceptibility of Helicobacter pylori to the rifamycin, rifaximin" 35 : 545-549, 1995

11 Avidan B, "The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication" 3 : 163-165, 2001

12 Kim N, "The effect of antibiotic resistance on the eradication of Helicobacter pylori" 47 : 82-86, 2006

13 정광현, "The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea" 거트앤리버 발행위원회 8 (8): 605-611, 2014

14 Sánchez JE, "Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones" 46 : 283-285, 2000

15 Hirata Y, "Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan" 39 : 352-355, 2012

16 Suzuki H, "Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation" 53 : 1720-1721, 2009

17 Murakami K, "Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations" 53 : 3097-3099, 2009

18 Gasbarrini A, "Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study" 24 : 195-200, 2006

19 De Giorgio R, "Rifaximin and Helicobacter pylori eradication" 1 : 105-110, 1997

20 Sang-Pil Yun, "Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori" 거트앤리버 발행위원회 6 (6): 452-456, 2012

21 Heep M, "Rifampin and rifabutin resistance mechanism in Helicobacter pylori" 43 : 1497-1499, 1999

22 Lim HC, "Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori" 19 : 455-461, 2014

23 Gisbert JP, "Review article: rifabutin in the treatment of refractory Helicobacter pylori infection" 35 : 209-221, 2012

24 Zullo A, "Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy" 25 : 1429-1434, 2007

25 Lee JW, "Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012" 18 : 206-214, 2013

26 Andersson T., "Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole" 31 : 9-28, 1996

27 Huynh HQ, "N-acetylcysteine, a novel treatment for Helicobacter pylori infection" 49 : 1853-1861, 2004

28 Murakami K, "Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan" 48 : 1128-1135, 2013

29 Malfertheiner P, "Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report" 61 : 646-664, 2012

30 Maehata Y, "Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer" 75 : 39-46, 2012

31 Saad RJ, "Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis" 101 : 488-496, 2006

32 Mégraud F, "In vitro activity of rifaximin against Helicobacter pylori" 13 : 184-186, 1994

33 Kawakami Y, "In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori" 44 : 458-461, 2000

34 Yang JC, "High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection" 13 : 895-905, 2015

35 Phan TN, "High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam" 45 : 244-248, 2015

36 김기방, "Helicobacter pylori 치료의 최신 지견:1차 제균 치료를 중심으로" 대한상부위장관ㆍ헬리코박터학회 14 (14): 237-241, 2014

37 이지현, "Helicobacter pylori 제균치료에서 Levofloxacin 병합요법의 효과" 대한소화기학회 48 (48): 19-24, 2006

38 Graham DY, "Helicobacter pylori treatment in the era of increasing antibiotic resistance" 59 : 1143-1153, 2010

39 Mégraud F, "H. pylori antibiotic resistance: prevalence, importance, and advances in testing" 53 : 1374-1384, 2004

40 Vakil N, "Eradication therapy for Helicobacter pylori" 133 : 985-1001, 2007

41 Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance" 208 : 1123-1130, 2013

42 Matsuzaki J, "Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies" 56 : 1643-1645, 2012

43 Liou JM, "Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial" 68 : 450-456, 2013

44 Grayson ML, "Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents" 8 : 888-889, 1989

45 Furuta T, "Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin" 69 : 158-168, 2001

46 Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial" 372 : 392-397, 2008

47 Conway BR., "Drug delivery strategies for the treatment of Helicobacter pylori infections" 11 : 775-790, 2005

48 Bayerdörffer E, "Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers" 108 : 1412-1417, 1995

49 Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea" 48 : 4843-4847, 2004

50 Ahn JY, "Current status of second-line and third-line therapy for Helicobacter pylori eradication in Korea" 10 : 1-5, 2010

51 Kim JM, "Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients" 28 : 6-13, 2006

52 Seck A, "Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal" 3 : 137-140, 2009

53 Graham DY, "Antibiotic resistance in Helicobacter pylori: implications for therapy" 115 : 1272-1277, 1998

54 Horiki N, "Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan" 14 : 86-90, 2009

55 Miehlke S, "An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively" 11 : 323-329, 1997

56 Gotoh A, "Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori" 7 : 183-191, 2002

57 Zullo A, "A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication" 35 : 232-236, 2003

58 Miehlke S, "A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin" 8 : 310-319, 2003

59 Gatta L, "A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses" 22 : 45-49, 2005